利妥昔单抗：一种用于皮肤病的B细胞清除疗法。

Rituximab: a B-cell depletion therapy for dermatologic disease.

作者信息

Prajapati V, Mydlarski P R

机构信息

Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.

出版信息

Skin Therapy Lett. 2007 Jul-Aug;12(6):6-9.

PMID:17762903

Abstract

Rituximab (Rituxan, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20, a B lymphocyte-specific antigen. Initially approved for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL), rituximab has been increasingly used to treat a variety of immune-mediated and autoimmune diseases. While anecdotal case reports recommend its "off-label" use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy of this emerging biologic therapy.

摘要

利妥昔单抗（美罗华，基因泰克/百健艾迪）是一种基因工程嵌合鼠/人单克隆抗体，靶向B淋巴细胞特异性抗原CD20。利妥昔单抗最初被批准用于治疗复发或难治性低度或滤泡性非霍奇金淋巴瘤（NHL），如今越来越多地用于治疗各种免疫介导和自身免疫性疾病。尽管有轶事病例报告推荐其在皮肤科的“非标签”使用，但仍需要随机临床试验来确定这种新兴生物疗法的安全性和有效性。